Labcorp Holdings Inc. (NYSE:LH) Stock Has Average Target Price of $337.73 According to Brokerages

Key Points

• Labcorp has a “Moderate Buy” consensus rating from 11 analysts, with seven buys, three holds and one strong buy. The average 12-month price target is $337.73, compared with the stock’s reported opening price of $329.10.
• Labcorp exceeded quarterly expectations, reporting $4.99 in adjusted EPS versus the $4.78 consensus and revenue of $3.73 billion, up 5.8% year over year. Analysts expect full-year EPS of approximately $18.32.
• The company declared a quarterly dividend of $0.72 per share, or $2.88 annually, representing a 0.9% yield and a 23.82% payout ratio; institutional investors own 95.94% of outstanding shares.

Shares of Labcorp Holdings Inc. (NYSE:LH - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $337.73.

LH has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a $306.00 price target on shares of Labcorp in a report on Friday, July 31st. Weiss Ratings upgraded shares of Labcorp from a "buy (b+)" rating to a "buy (a-)" rating in a report on Wednesday. Barclays boosted their price objective on shares of Labcorp from $320.00 to $330.00 and gave the company an "equal weight" rating in a research report on Friday, September 11th. Truist Financial upped their target price on shares of Labcorp from $350.00 to $365.00 and gave the stock a "buy" rating in a research note on Monday, September 21st. Finally, Morgan Stanley upped their target price on shares of Labcorp from $308.00 to $338.00 and gave the stock an "overweight" rating in a research note on Friday, July 31st.

Labcorp Trading Up 0.0%

Shares of NYSE LH opened at $329.10 on Monday. The company's fifty day moving average is $320.94 and its 200-day moving average is $291.11. The stock has a market cap of $26.69 billion, a price-to-earnings ratio of 27.22, a P/E/G ratio of 1.88 and a beta of 0.87. Labcorp has a twelve month low of $244.52 and a twelve month high of $341.80. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69.

Labcorp (NYSE:LH - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.71 billion. During the same quarter in the previous year, the business earned $4.35 EPS. The firm's revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities research analysts predict that Labcorp will post 18.32 EPS for the current year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Tuesday, November 24th. Labcorp's payout ratio is 23.82%.

Insider Transactions at Labcorp

In other news, Director Kerrii Anderson sold 3,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the transaction, the director directly owned 6,563 shares of the company's stock, valued at $2,087,165.26. This represents a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Amy Summy sold 924 shares of the stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares of the company's stock, valued at approximately $2,133,683.44. The trade was a 11.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 8,593 shares of company stock valued at $2,733,295 over the last three months. Company insiders own 0.84% of the company's stock.

Hedge Funds Weigh In On Labcorp

A number of large investors have recently bought and sold shares of LH. Fifth Third Bancorp grew its position in Labcorp by 106.5% in the first quarter. Fifth Third Bancorp now owns 57,981 shares of the medical research company's stock valued at $15,470,000 after purchasing an additional 29,899 shares in the last quarter. Public Employees Retirement System of Ohio bought a new stake in Labcorp during the 2nd quarter worth about $7,792,000. Tidal Investments LLC lifted its position in Labcorp by 12.4% during the 2nd quarter. Tidal Investments LLC now owns 30,559 shares of the medical research company's stock worth $8,557,000 after buying an additional 3,372 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new position in shares of Labcorp during the 2nd quarter worth about $168,222,000. Finally, Royal Bank of Canada boosted its stake in shares of Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company's stock worth $218,901,000 after buying an additional 133,549 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company's stock.

About Labcorp

Labcorp NYSE: LH, formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women's health testing, genetic testing, pathology services and other laboratory services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.